Skip to main content
    M

    Mink Therapeutics Inc (INKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.26
    -0.08 (-0.86%)

    Market Cap: $47.95M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Mink Therapeutics Inc (INKT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 11, 2026. Financial statements from company filings, amounts in US dollars.

    Mink Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$12.49M, operating cash flow was -$5.93M and free cash flow was -$5.93M. The quarter ended Sep 30, 2026 had revenue of $200.00K and net income of -$2.55M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $12.64M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$689.63KN/A100.0%-3231.4%-3451.5%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$0$0$0$0$0$689.63K
    Gross profit$0$0$0$0$0$0$689.63K
    Research and development$5.76M$6.34M$15.49M$23.12M$13.97M$9.51M$19.65M
    Operating income-$12.64M-$11.29M-$22.92M-$30.95M-$28.36M-$14.64M-$22.28M
    Net income-$12.49M-$10.78M-$22.46M-$27.99M-$30.21M-$16.24M-$23.80M
    EBITDA-$12.49M-$10.74M-$22.72M-$28.12M-$28.06M-$13.74M-$22.20M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$200.00K$0$0$0$0$0$0$3.77B$0$0$0-$11.71B
    Gross profit$200.00K$0$0-$38.56K$0$0$0-$53.87K$0$0$0-$53.57K
    Operating income-$2.64M-$3.22M-$2.88M-$2.71M-$3.18M-$4.05M-$2.70M-$2.50M-$1.88M-$3.07M-$3.83M-$5.50M
    Net income-$2.55M-$3.13M-$2.74M-$2.60M-$2.89M-$4.24M-$2.77M-$2.46M-$1.81M-$2.70M-$3.81M-$5.46M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $5.18M by $8.18M. Shareholder equity was negative, at -$14.23M, as total liabilities of $28.47M exceeded total assets of $14.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$14.24M$5.72M$4.55M$21.47M$40.24M$4.56M$1.31M
    Current assets$13.85M$4.99M$3.60M$20.40M$39.63M$4.10M$918.40K
    Cash and equivalents$13.36M$4.58M$3.37M$19.64M$38.89M$2.69M$299.04K
    Total liabilities$28.47M$25.31M$22.61M$21.87M$16.47M$58.43M$37.64M
    Short-term debt$5.18MN/AN/AN/AN/AN/A$4.76M
    Long-term debt$0$4.92M$0$0$0$43.82M$26.79M
    Shareholder equity-$14.23M-$19.59M-$18.06M-$401.30K$23.78M-$53.87M-$36.33M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$8.24M$9.62M$10.38M$14.24M$14.96M$2.48M$4.27M$5.72M$7.37M$10.32M$6.89M$4.55M
    Total liabilities$24.49M$23.64M$23.06M$28.47M$28.48M$27.67M$26.06M$25.31M$24.93M$26.90M$27.19M$22.61M
    Cash and equivalents$7.47M$8.81M$9.53M$13.36M$14.28M$1.68M$3.23M$4.58M$6.33M$9.31M$5.82M$3.37M
    Shareholder equity-$16.25M-$14.03M-$12.69M-$14.23M-$13.51M-$25.19M-$21.79M-$19.59M-$17.55M-$16.58M-$20.30M-$18.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$5.93M-$9.56M-$15.76M-$18.87M-$12.83M-$8.34M-$14.94M
    Capital expenditures$0$0$73.56K$250.05K$248.98K$95.21K$426.47K
    Free cash flow-$5.93M-$9.56M-$15.84M-$19.12M-$13.08M-$8.43M-$15.37M
    Share repurchases$173.35K$0$477.64K$157.19KN/AN/AN/A
    Investing cash flow$0$0-$73.56K-$250.05K-$248.98K-$95.21K-$426.47K
    Financing cash flow$14.72M$10.82M-$407.17K-$155.60K$49.26M$11.11M$11.44M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.28M-$2.08M-$1.73M-$2.07M-$941.35K-$1.57M-$1.34M-$1.73M-$2.99M-$2.29M-$2.54M-$3.04M
    Capital expenditures$56.72KN/A$0$3$2$0$0$0$0$0$0$73.56K
    Free cash flow-$1.33MN/A-$1.73M-$2.07M-$941.35K-$1.57M-$1.34M-$1.73M-$2.99M-$2.29M-$2.54M-$3.11M
    Last 12 quarters

    Frequently Asked Questions About INKT

    What is Mink Therapeutics' annual revenue?

    Mink Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Mink Therapeutics profitable?

    No. Mink Therapeutics reported net income of -$12.49M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does INKT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.93M minus capital expenditures of $0 produced free cash flow of -$5.93M.

    How much debt does Mink Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $5.18M and cash and equivalents of $13.36M.